•Elimination of Lipid Interference: High-lipid sample treatment agents disperse lipoproteins and immune complexes in lipid-rich samples (e.g., serum, plasma) through emulsification, reducing light scattering interference and improving the signal-to-noise ratio in chemiluminescence or immunoturbidimetric assays.

•Colloidal Gold Stabilization: In immunochromatographic assays, these agents act as stabilizers to prevent aggregation of colloidal gold particles, avoiding false-negative results, while also aiding in cell membrane lysis to release antigens.

•Hard Water Resistance: High-lipid sample treatment agents exhibit strong tolerance to calcium and magnesium ions, minimizing the impact of water quality variations on test results.

•Thickening and Stabilization: As emulsifiers and thickeners, these agents optimize reagent viscosity, enhancing reaction homogeneity in chemiluminescence reagents and improving the shelf-life stability of test kits.

•Compatibility with Hemolyzed/Lipemic Samples: By dispersing lipid substances, these agents reduce interference from hemolyzed or lipid-rich samples in optical detection methods (e.g., turbidimetry, spectrophotometry).

•Reagent Preparation: Dissolve the high-lipid sample treatment agent (0.5%–2% w/w) and PEG 6000 (3%–10% w/w) in deionized water. Heat to 40°C while stirring until the solution becomes transparent.

•Sample Mixing: Mix the treatment solution with the serum sample at a ratio of 1:3 to 1:5. Vortex for 5 minutes.

•Centrifugation: Centrifuge at 3,000 rpm for 10 minutes and collect the supernatant for detection.

•Step a: Add the high-lipid sample treatment agent solution to the high-lipid sample (e.g., serum) to a final concentration of 0.5%–1% (e.g., add 5–10 μl of the stock solution to 1 ml of sample).

•Incubate the mixture at 37°C for 10 minutes to promote emulsification and dispersion of lipid particles.

•Centrifuge at 12,000 rpm for 10 minutes to remove large lipoprotein complexes and collect the lower clear liquid.

•Step b: Mix the pre-treated clear liquid with a 20% PEG 6000 solution at a 1:1 volume ratio (e.g., 100 μl sample + 100 μl PEG solution).

•Let it stand at room temperature for 30 minutes to precipitate lipoproteins.

•Centrifuge at 12,000 rpm for 20 minutes and collect the supernatant for detection.

•Note: The one-step method is suitable for samples with low to moderate lipid levels, while the two-step method is recommended for highly lipid-rich samples.

•Precaution: Validate the compatibility of the high-lipid sample treatment agent with target antigens/antibodies to avoid signal suppression due to surfactant encapsulation.

•Colloidal Gold Labeling Optimization: Add the high-lipid sample treatment agent (0.5%–1.5% w/w) to the colloidal gold labeling buffer to prevent marker aggregation and improve labeling efficiency.

•Reaction System Control: Combine the high-lipid sample treatment agent with Tween-20 to adjust the wettability of the nitrocellulose (NC) membrane, optimizing flow speed and detection sensitivity.

•Chemiluminescence Detection: After treatment with the high-lipid sample treatment agent, the lipid clearance rate in chylous serum samples reaches 85%–90%, and the signal-to-noise ratio improves to 1:12 (compared to 1:8 in untreated samples).

•Immunoturbidimetry: In C-reactive protein (CRP) detection, the agent reduces the false-positive rate in lipid-rich samples by approximately 20%.

•Open-Bottle Stability: Reagents containing the high-lipid sample treatment agent maintain stable performance for up to 72 hours when stored at 4°C after opening, avoiding gelation or precipitation.

•Freeze-Thaw Resistance: When combined with glycerol, the agent improves the low-temperature tolerance of reagents, with ≤5% activity loss after three freeze-thaw cycles at -20°C.

•Automation Compatibility: The low-temperature fluidity of the high-lipid sample treatment agent supports continuous sampling in fully automated chemiluminescence analyzers, reducing manual intervention.

•Avoid direct mixing of the high-lipid sample treatment agent with strongly acidic/alkaline reagents (e.g., EDTA, SDS). Dilute first to prevent precipitation or signal suppression.

•The agent may precipitate at pH <6.5. Strictly adjust the buffer system to avoid this issue.

•Routine Testing: Such as lipid profiles, CRP tests, and other chemiluminescence or turbidimetric assays.

•Low-to-Medium Sensitivity Platforms: Laboratories with cost sensitivity and moderate lipid interference in samples.

•For samples containing high concentrations of bilirubin (>50 μmol/L) or hemoglobin (>5 g/L), additional anti-interference agents (e.g., potassium ferrocyanide) are required.